Kite Pharma, Inc.

John M Rossi

Adrian I Bot

Yizhou Jiang

Xiaodong Xue

William Y Go

The disclosure provides methods of treating a malignancy comprising administering an effective dose of a chimeric receptor (e.g., CAR or TCR) genetically modified T cell immunotherapy. Some aspects of the disclosure relate to methods of characterizing the pre-infusion tumor microenvironment and determining an effective dose of a T cell immunotherapy.

Chimeric receptor T cell treatment using characteristics of the tumor microenvironment

The disclosure provides methods of treating a malignancy comprising administering an effective dose of a chimeric receptor (e.g., CAR or TCR) genetically modified T cell immunotherapy. Some aspects of the disclosure relate to methods of determining an effective dose of a T cell immunotherapy comprising polyfunctional T cells prior to administration to the patient.

Growing community of inventors

Santa Monica, CA, United States of America

John M Rossi